1. Age ≥ 18 years
2. Cytologically or histologically confirmed NSCLC and must have archival diagnostic tissue available for analysis
3. Clinical or radiographic progression during or after first-line chemotherapy treatment for Stage IIIB/IV disease
4. Must not have had prior therapy with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent
5. No history of gross hemoptysis in the prior 3 months.
6. ECOG performance status of 0, 1, or 2

1. Age ≥ 18 years
2. Pathologic diagnosis of NSCLC and current stage IIIB (with pleural effusion) or IV, not curable with conventional therapy. A sample of tumor must be available.
3. Must have progressive disease following at least 12 weeks of therapy with Tarceva or Iressa
4. No active brain metastases
5. No more than 2 prior chemotherapy regimens for relapsed or metastatic disease. No prior therapy with EGFR/HER-2 targeted therapy
6. ECOG performance status 0 – 2
7. Patients must have normal bone marrow, liver, heart and kidney function.

1. Age > 18 years.
2. Stage IIIB or Stage IV NSCLC that has been histologically or cytologically confirmed with documented disease progression
3. One prior line of conventional cytotoxic chemotherapy for Stage IIIB or Stage IV disease not to include any anti-epidermal growth factor receptor (EGFR) antibody or anti-EGFR tyrosine kinase inhibitor
4. Normal bone marrow, kidney and liver function
5. Must have ECOG performance status 0 or 1
6. Life expectancy of > 3 months

1. Must have histologically confirmed BAC or adenocarcinoma with BAC features and stage IIIB (malignant pleural effusion) or stage IV disease
2. Must have disease that has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (Iressa or Tarceva)
3. Must have radiographic documentation of progressive disease and measurable disease by RECIST
4. Must be 18 years of age or older
5. Must have life expectancy greater than 3 months
6. Must have ECOG performance status of 0, 1, or 2

This research study is being conducted in patients with advanced lung cancer that cannot be treated with surgery or radiation therapy, and which no longer responds to chemotherapy. The purpose of this study is to find out if BAY 43-9006 (the study drug) will slow the growth of the cancer in patients who receive extended treatment with BAY 43-9006 compared to those who do not continue on the treatment right away but have a “break” until their cancer starts to grow. 
After two months of treatment on the study, the cancer will be evaluated. If the cancer is worse, participation in the study will end and other treatment options will be discussed. If the cancer is the same, participation will continue and the patient will be randomized (put into a treatment group by chance, like the flip of a coin) to continue receiving more therapy with either BAY 43-9006 or a placebo. 

1. Have documented advanced non-small cell lung cancer;
2. Have had at least two prior chemotherapy regimens for non-small cell lung cancer and must have progressing disease;
3. Be 18 years of age or older;
4. Have good organ function;
5. Not have clinically evident congestive heart failure, serious arrhythmias, or symptoms of coronary heart disease; 
6. Not have an active secondary malignancy or a clinically serious active infection;

1. Patients must have a confirmed diagnosis of Stage III or IV non-small cell lung cancer, or recurrent disease and failed first and second-line chemotherapy regimens.
2. Patients may not have received the study agent, PT-523, prior to entry into 
   the study.
3. Patients must be asymptomatic or treated brain metastases if last therapy was received before fours week entry into the study.
4. At least four week must have elapsed from the time of major surgery, and 
   patients must have recovered from any effects of any significant procedures.
5. There must be a 3 week interval from the last does of chemotherapy prior to 
   beginning the protocol therapy. Palliative radiotherapy to bony sites of disease is 
   permissible.
6. Patients must have an ECOG performance stays of 0-2.
7. Patients must have normal organ and bone marrow function within 14 days of 
   entry into the study

1. Patients must have histologically or cytologically confirmed recurrent SCLC with clinically confirmed measurable disease. X-rays or scans used to document measurable disease must be obtained within 4 weeks prior to registration.
2. Patients must have had prior chemotherapy treatment for SCLC. 
3. Patients must not have had radiation therapy or chemotherapy within 60 days of registration.
4. Patients must not have had any prior paclitaxel or interferon alpha therapy.
5. Patients must have normal kidney, liver and bone marrow function.

1. Patients must have sensitive (progression greater than or equal to 90 days after completing first-line therapy) relapsed small cell lung cancer.
2. Patients may have received prior chemotherapy or radiation therapy.
3. Patients must have a life expectancy of at least 12 weeks.
4. Patients with brain metastasis are eligible if they have stable brain disease and are no longer receiving irradiation and do not require steroids to control symptoms.
5. Patients must have normal bone marrow, liver and kidney function.

1. Patients must have non-metastatic, inoperable, Stage IIIA or IIIB histologically or cytologically documented NSCLC without evidence of malignant pleural effusion.
2. Patients must not have received any prior systemic chemotherapy, thoracic radiotherapy or surgical resection for treatment of NSCLC.
3. Patients must have at least one site of unidirectionally measurable disease.
4. Patients must be more than 3 weeks from a formal exploratory thoracotomy.
5. Patients must have normal bone marrow, kidney and liver function.

1. Patients must have selected Stage IIB, IIIA or IIIB non-small cell lung cancer due to involvement of the superior sulcus.
2. Patients must have either histologic or cytologic proof of a newly diagnosed single primary bronchogenic non-small cell lung cancer.
3. Patients with either pericardial effusions or superior vena cava syndrome are not eligible.
4. Patients must not have any evidence of distant metastatic disease.
5. Patients must have normal bone marrow, kidney and liver function.

1. Patients must have either histologic or cytologic evidence of a single, primary bronchogenic non-small cell lung cancer.
2. Patients with two or more distinct parenchymal lesions on same or opposite sides of the lung are not eligible.
3. Patients must have Stage IIIB disease.
4. Patients must not have received any prior chemotherapy or radiotherapy for lung cancer. 
5. Patients must have normal bone marrow, liver, kidney, cardiac and lung function.
6. Patients must be at least 18 years of age.

1. Undergone complete resection of a histologically proven Stage 1A or 1B non-small cell lung cancer and currently free of disease
2. Must be between 6 months and 36 months from date of surgical resection
3. Must not have received chemotherapy or radiotherapy for lung cancer
4. Must be 18 years of age or older
5. Normal hepatic function
6. ECOG performance status of 0-1
7. Must not be taking mineral, herbal, phytochemical, or vitamin supplements at time of entry

1. Histologically confirmed invasive, recurrent or metastatic thymoma or thymic carcinoma not amenable to curative therapy by surgery

2. Must have measurable disease

3. No prior chemotherapy for metastatic disease

4. Adequate hepatic, renal , and hematologic function

5. Must be 18 years or older

6. ECOG performance status of 0 or 1

7. No acute infection or post-surgical complications

8. Pregnant or nursing women are excluded

1. Patients must have histologically confirmed malignant pleural or peritoneal mesothelioma epithelial, sarcomatoid, or mixed subtype, not amenable to curative treatment with surgery.

2. Patients may have undergoing pleurodesis. If pleurodesis was performed, there must be at least a 2-week delay before ALIMTA or gemcitabine is administered.

3. Patients must have an estimated life expectancy of at least 12 weeks.

4. Patients must have adequate bone marrow, hepatic and renal function.

5. Patients must not have received prior systemic chemotherapy.  Prior intracavitary cytotoxic drugs are not permitted, unless given for the purpose of pleurodesis.

6. Patients must not have received prior radiation therapy to the target lesion, unless the lesion is clearly progressi